R&D Views & Analysis | pharmaphorum

Views & Analysis

Osteoporosis treatment options - down to the bare bones

It is World Osteoporosis Day this month, and Ben Hargreaves takes a look at what treatment options look like for patients living with the disease.

Views & Analysis

How to Successfully Employ External Comparator Arm Studies U...

Despite randomised clinical trials (RCTs) being the gold standard for drug approval studies, the shift towards precision medicine has increased the use of single-arm trials (SATs).

Views & Analysis

Field of burning oil wells, Persian Gulf War

Gulf War Illness: How can disease modelling aid the search f...

Biological systems are hugely complex, with a staggering number of pathways interacting every millisecond. The downstream effects of just one biological change are enormous.

News

Amylyx ALS drug draws criticism over $158,000 price tag

Amylyx Pharmaceuticals’ Relyvrio – a new treatment for amyotrophic lateral sclerosis (ALS) approved by the FDA on Thursday, after review of the data from its phase 2 trial – was the next da

Videos

Health Innovators – Dr. Houda Hachad

Dr.

Views & Analysis

Lilly’s Mounjaro wins latest head-to-head battle in clinical...

Diabetes is one of the most common health conditions in the United States, afflicting more than 11% of the population, with over 90% included in the type 2 category.

Osteoporosis treatment options - down to the bare bones

How to Successfully Employ External Comparator Arm Studies U...

Gulf War Illness: How can disease modelling aid the search f...

Amylyx ALS drug draws criticism over $158,000 price tag

Health Innovators – Dr. Houda Hachad

Lilly’s Mounjaro wins latest head-to-head battle in clinical...

Bankruptcy threat looms as Quince runs out of options

How to meet your physicians where they are online

Views & Analysis

Editor's Picks